Cytosine arabinoside in the treatment of acute myeloblastic leukaemia.
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000606:Amino Sugars / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D005500:Follow-Up Studies; D006027:Glycosides / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011247:Pregnancy; D012075:Remission, Spontaneous; D013997:Time Factors
D000606:Amino Sugars; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D006027:Glycosides; D003561:Cytarabine; D011239:Prednisolone; D015122:Mercaptopurine